Company Overview
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona's lead clinical program is EB-101, its investigational autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa in Phase 3 development. The Company's development portfolio also features AAV-based gene therapies for ophthalmic diseases with high unmet medical need.

Abeona Therapeutics Reports Third Quarter 2022 Financial Results
Nov 14 2022, 7:30 AM EST

Abeona Therapeutics Announces $35 Million Private Placement Financing
Nov 3 2022, 7:31 AM EDT

Abeona Therapeutics Announces Positive Topline Results with Both Co-Primary Endpoints Met in Pivotal Phase 3 VIITAL™ Study of EB-101
Nov 3 2022, 7:30 AM EDT

Management Team
Vishwas Seshadri, Ph.D., M.B.A.
Chief Executive Officer, Director

Brian Kevany, Ph.D.
VICE PRESIDENT, CHIEF TECHNICAL OFFICER AND HEAD OF RESEARCH

Joseph Vazzano
Chief Financial Officer

Greg Gin
Vice President, Investor Relations and Corporate Communications

Alison Hardgrove
Vice President, Human Resources

Brendan O'Malley, J.D., Ph.D.
Senior Vice President, General Counsel

Madhav Vasanthavada
Vice President, Business Development

Stock Overview
Symbol ABEO
Exchange Nasdaq
Market Cap 64.58m
Last Price $3.76
52-Week $2.7001 - $17.50

Investor Relations
ir@abeonatherapeutics.com

Abeona Therapeutics Inc.
1330 Avenue of the Americas
33rd Floor
New York, NY 10019

Disclaimer
Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.